Amphastar Pharmaceuticals AMPH US — Non-Current Assets
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NoncurrentAssets.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's us — non-current assets.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's US — non-current assets?
- Amphastar Pharmaceuticals (AMPH) reported US — non-current assets of $235.03M in Q1 2026.
- How has Amphastar Pharmaceuticals's US — non-current assets changed year-over-year?
- Amphastar Pharmaceuticals's US — non-current assets increased by 12.8% year-over-year, from $208.3M to $235.03M.
- What is the long-term trend for Amphastar Pharmaceuticals's US — non-current assets?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's US — non-current assets has grown at a 11.8% compound annual growth rate (CAGR), from $530.03M to $829.02M.
- What does US — non-current assets mean?
- This metric captures the long-term assets held by the company within its United States operations that are not expected to be converted to cash within a single fiscal year. It includes investments in infrastructure, intellectual property, and long-term capital projects essential for sustaining domestic manufacturing and distribution capabilities. Monitoring this balance helps assess the scale of the company's long-term capital commitment to its domestic business segment.